Omalizumab对过敏性支气管肺曲霉病患者病情加重和糖皮质激素使用的影响:系统评价和荟萃分析

{"title":"Omalizumab对过敏性支气管肺曲霉病患者病情加重和糖皮质激素使用的影响:系统评价和荟萃分析","authors":"W. Calhoun, M. Jin, J. Douglass, J. Elborn, R. Agarwal, S. Lazarewicz, M. Yan","doi":"10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1235","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":262576,"journal":{"name":"A31. REAL WORLD ASTHMA TREATMENT OUTCOMES, BIOMARKER STUDIES, PHENOTYPING, AND SEVERITY ASSESSMENTS","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Effect of Omalizumab on Exacerbations and Glucocorticoid Use in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis\",\"authors\":\"W. Calhoun, M. Jin, J. Douglass, J. Elborn, R. Agarwal, S. Lazarewicz, M. Yan\",\"doi\":\"10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1235\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":262576,\"journal\":{\"name\":\"A31. REAL WORLD ASTHMA TREATMENT OUTCOMES, BIOMARKER STUDIES, PHENOTYPING, AND SEVERITY ASSESSMENTS\",\"volume\":\"5 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"A31. REAL WORLD ASTHMA TREATMENT OUTCOMES, BIOMARKER STUDIES, PHENOTYPING, AND SEVERITY ASSESSMENTS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1235\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"A31. REAL WORLD ASTHMA TREATMENT OUTCOMES, BIOMARKER STUDIES, PHENOTYPING, AND SEVERITY ASSESSMENTS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}